Wide-field mosaics of the corneal subbasal nerve plexus in Parkinson’s disease using in vivo confocal microscopy

Reza A. Badian1, Stephan Allgeier2, Fabio Scarpa3, Mattias Andréasson4,5,6, Andreas Bartschat2, Ralf Mikut2, Alessia Colonna3, Marco Bellisario7, Tor Paaske Utheim8,9, Bernd Köhler2, Per Svenningsson4,5,6 & Neil Lagali7,9

Background & Summary

Neurological disorders are a significant cause of disability and death worldwide. In the period from 1990 to 2015, the number of deaths from neurological disorders increased by 36.7%, with Parkinson’s disease (PD) constituting the 12th most common condition leading to premature death (1.2%) among all neurological disorders in the overall global burden from neurological disorders in 20151.

PD is a progressive neurodegenerative disorder with its diagnosis based on clinical criteria consisting of a combination of bradykinesia with rigidity and/or rest tremor2. Peripheral neuropathy (PN) that occurs in PD can exhibit both small and large fiber involvement3,4. Additionally, restless legs syndrome (RLS), a sensorimotor condition, is frequently reported among patients suffering from neurological disorders including PD; therefore occurrence of RLS as comorbidity in PD patients has been the focus of multiple studies5–8. As PN is difficult to diagnose, there has been much interest in the development and refinement of non-invasive examination modalities for its potential diagnosis. Increasingly, quantitative measures derived from non-invasive peripheral nerve imaging in the corneal subbasal nerve plexus are being reported as putative indicators of small fiber peripheral neuropathy in conditions such as diabetes mellitus9–17. This technique is therefore of interest in the context of PD and RLS.

The cornea is a densely innervated tissue, whose sensory nerve bundles enter the cornea at the mid-stroma in a radial formation from the periphery18–21. The stromal branches extend towards the central anterior cornea.
In vivo confocal microscopy (IVCM) is a clinical method of non-invasively examining the cornea, providing images with high lateral (1–2 µm) and axial (5–10 µm) resolution, at a magnification of up to 600× to 800 times33. IVCM provides excellent images of the SBNP, from which parameters such as corneal nerve fiber length density (CNFL, measured as the sum of the nerve fiber length in mm divided by the corresponding SBNP area in mm²), corneal nerve fiber number density (CNFD, the number of distinct nerve fibers (defined in various ways) per mm² of SBNP area), corneal nerve branch density (CNBD, the number of nerve branching points per mm² of SBNP area), and tortuosity (defined in various ways) can be measured10,16,18,20,25,26. Only a few studies have used IVCM to examine corneal nerves in PD with some contradictory results. One study included 26 PD patients with varying disease duration and 26 controls. Using IVCM and selecting 4 to 6 single field-of-view images per eye for analysis, reduced CNFD, but increased CNBD and CNFL were found, compared to (healthy) controls37. Another IVCM study, including 26 patients with early PD and 22 controls, analyzed 4 to 8 single field-of-view IVCM images of the SBNP per subject. The authors of the study reported that CNFL and CNBD were significantly reduced in PD patients compared to controls, while CNFD reduction was not statistically significant38. Another study assessing 15 patients with moderate PD and 15 healthy controls, did not report the number of IVCM images analyzed per eye, but found a significant reduction in CNFL in PD patients relative to controls39.

Here we present an IVCM dataset representing a larger number of patients (n = 42) compared to prior IVCM studies of PD. The raw data in this dataset was originally used30 to investigate a possible relationship between non-invasively examining the cornea, providing images with high lateral (1–2 µm) and axial (5–10 µm) resolution, at a magnification of up to 600× to 800 times33. IVCM provides excellent images of the SBNP, from which parameters such as corneal nerve fiber length density (CNFL, measured as the sum of the nerve fiber length in mm divided by the corresponding SBNP area in mm²), corneal nerve fiber number density (CNFD, the number of distinct nerve fibers (defined in various ways) per mm² of SBNP area), corneal nerve branch density (CNBD, the number of nerve branching points per mm² of SBNP area), and tortuosity (defined in various ways) can be measured10,16,18,20,25,26. Only a few studies have used IVCM to examine corneal nerves in PD with some contradictory results. One study included 26 PD patients with varying disease duration and 26 controls. Using IVCM and selecting 4 to 6 single field-of-view images per eye for analysis, reduced CNFD, but increased CNBD and CNFL were found, compared to (healthy) controls37. Another IVCM study, including 26 patients with early PD and 22 controls, analyzed 4 to 8 single field-of-view IVCM images of the SBNP per subject. The authors of the study reported that CNFL and CNBD were significantly reduced in PD patients compared to controls, while CNFD reduction was not statistically significant38. Another study assessing 15 patients with moderate PD and 15 healthy controls, did not report the number of IVCM images analyzed per eye, but found a significant reduction in CNFL in PD patients relative to controls39.

**Methods**

**Study design, participants, inclusion and exclusion criteria.** The initial study from which the raw IVCM data was collected30 had a cross-sectional design, where participants were enrolled in the period from Spring 2018 to Autumn 2019 at the outpatient clinic at Center for Neurology and Karolinska University Hospital, Stockholm, Sweden. The study encompassed control participants without PD, and PD patients with (PD + RLS) and without RLS (PD-RLS) matched for age and sex. Participants were aged between 50 and 80 years and had to have one eye without history of previous corneal trauma, surgery or ongoing eye drop treatment. Patients fulfilled a diagnosis of clinically probable PD with or without RLS according to established criteria24. PD + RLS (n = 21), PD – RLS (n = 21) and controls (n = 13) comprised the study. Written informed consent was obtained from all participants and the study was approved by the regional ethical board of Stockholm, Sweden (ref. nr 2018/264-31/2 (2019-03158)). Inclusion and exclusion criteria have been previously described in detail35.

**Clinical assessments.** Details of the clinical, neurophysiological and biochemical assessments are outlined in our original study report30. In short, demographic and disease-specific parameters were obtained by oral interview. Neurological rating scales included modified Hoehn and Yahr staging (mH&Y)37,38 and the Utah Early Neuropathy Scale (UENS)39. The severity of RLS symptoms was evaluated with the International Restless Legs Scale rating scale (IRLS)40 and the sensory suggested immobilization test was performed in the PD + RLS group31,42. With regard to electrodagnostic and quantitative sensory testing, details are described in the original study report30.

**In Vivo Confocal Microscopy Examination.** In vivo confocal microscopy of the cornea was performed to visualize the peripheral small fiber morphology of the corneal SBNP. IVCM image acquisition was conducted in both eyes of all participants, or in one eye in cases where the other eye did not meet the inclusion criteria. A single, experienced examiner performed all examinations using a Heidelberg Retinal Tomograph 3 with Rostock Corneal Module, HRT3-RCM (Heidelberg Engineering, Germany), using a built-in fixation light to bring the focus on to the central cornea. A motorized joystick module was used to control and maintain the focal plane at the desired corneal depth, at the SBNP level. The central and paracentral corneal regions were first imaged by translating the microscope field of view manually in a raster pattern, until regions were reached where the curvature of the cornea resulted in oblique images. Subsequently, to image the paracentral regions, the fixation light was moved sequentially in superior, inferior, temporal and nasal direction, with the manual raster scanning process being repeated for each fixation light position. During scanning, the depth of the SBNP was maintained.
by manually adjusting the depth of focus by small movements on the joystick, in order to capture subtle variations in the plexus and enable a maximal projection of nerves to be made onto a 2D plane, as previously described\textsuperscript{31}.

Differing from prior work, however, during the clinical examinations an attempt was made to image as large a wide-field area of the SBNP as possible by periodically pausing the examination to allow the subject and examiner to rest, then resuming the examination, until the examiner judged the imaged area to be of sufficient extent and quality, provided the subject was willing to cooperate with the strategy. The raw image datasets obtained from IVCM examination were then used as input to automated mosaic generation and nerve detection and quantification algorithms (described below).

**Automated mosaic image generation.** The process used to assemble SBNP mosaic images from the acquired datasets is identical to the method described in previous studies\textsuperscript{16,31}, with one notable exception described below. The mosaic generation process consisted of four consecutive process steps:

1. **Removal of non-SBNP images from the dataset,**
2. **Pairwise, correlation-based image registration (using a decomposition of the images into 12 horizontal rectangular sub-images),**
3. **Formation and solution of a system of linear equations, yielding position coordinates of the sub-images,** and
4. **Construction of the mosaic image.**

As it is not always possible to avoid the inclusion of non-SBNP images in the acquired datasets, these images were first removed from the processed data. The benefit of this is twofold. Non-SBNP images could negatively influence the contrast of the relevant SBNP image features if included in the mosaic algorithm, and removal of such images reduces mosaic-processing time if excluded early in the processing pipeline. Whereas the exclusion of non-SBNP images had been done manually in the past\textsuperscript{31}, a tissue classification algorithm\textsuperscript{43} was used in the initial PD\textsuperscript{10} study to automatically identify and exclude non-SBNP images. The classifier is based on the Bag of Visual Words approach. It uses a trained feature extraction followed by a set of support vector machines, each of which had been trained to separate one characteristic corneal tissue class (epithelium, SBNP, stroma) from any other tissue class. A previous quantitative evaluation of the classifier reported a classification accuracy of over 96% on a manually labeled set of 663 IVCM images\textsuperscript{43}.

The image registration step makes use of the phase correlation function, a well-established approach for calculating the relative offset between two images\textsuperscript{44}. The phase correlation was calculated for all possible image pairs of a dataset to establish an estimation of the translational alignment between each image pair, but the key step in creating high-quality mosaic images is the decomposition of each image into 12 horizontal slices or sub-images and the calculation of the relative alignment $d_j$ (relating to the sub-images with indices $i$ and $j$)\textsuperscript{31,45}. This approach was designed to analyze specifically the characteristic motion-induced image deformation artifacts that arise from the image formation process of the HRT-RCM microscope.

The third step of the mosaic generation process was the deduction of absolute, global position coordinates $p_i$ for the sub-images from the translation vectors $d_j$ that had been calculated in the registration step. This global alignment process is based on the observation, that the translation vectors effectively estimate the position differences between respective sub-images, $d_{ij} = p_j - p_i$\textsuperscript{31,46}. After excluding all sub-image registration results with a correlation value below an empirically predefined threshold, these equations form a system of linear equations. The linear equation system always possesses degrees of freedom that need to be addressed by additional regularization terms: An additional equation $\lambda_1 p_0 = 0$ complements the otherwise purely difference equations with an absolute reference, and equations $\lambda_j (p_{i+1} - p_i) = 0$ (limited to pairs $(i, i+1)$ of sub-images that belong to the same original image) provide alignment information for sub-images without any accepted registrations; $\lambda_1$ and $\lambda_j$ are weight factors. The regularized system of linear equations is subsequently solved for the sub-image position coordinates $p_j$.

The final mosaic image construction step was implemented as described previously\textsuperscript{31}. Appropriate interpolation between the sub-image positions $p_j$ yields position coordinates for single image rows, and the final mosaic image was then calculated by weighted averaging of overlapping original image data.

**Optimizations of the mosaic image generation process.** Runtime considerations were not a priority in the context of the present dataset. However, with regard to potential application in routine clinical practice (and also with regard to a larger number of patients in the future), the mosaic image generation process was reexamined with a particular focus on runtime optimization. The most effective means to reduce runtime is a size reduction of the images in the context of the image registration step, as the calculation time of the correlation function is dependent on the size of the input data. However, reducing the image information used for the correlation function inherently increases the noise level of the correlation function, making it harder to reliably separate correct registration results from incorrect ones. Scale factors of 3 and 2 for full image and sub-image correlations, respectively, have proven to be a good compromise.

**Automated nerve tracing and nerve parameter quantification in SBNP mosaics.** The algorithm used for automated nerve fiber tracing in mosaics was described earlier by Guimarães et al.\textsuperscript{46}. Briefly, this algorithm is based on three main steps: pre-processing, classification and post-processing. The pre-processing aims to improve the visibility of the corneal nerves. To achieve this goal, a Top-Hat morphological filtering was used to equalize the background and to improve the contrast of the image. A bank of log-Gabor filters, each with a different orientation, highlights linear structures and completes the pre-processing. A threshold was then applied...
To identify pixels corresponding to a nerve. From the selected pixels, morphological and intensity-based features are extracted and used as input for a finer classification based on the support vector machines approach. The final classification consists in a label “nerve” or “other” assigned to each pixel of the image. A binary image was then obtained, in which white pixels correspond to nerves and black pixels correspond to the other.

The resulting binary image contains nerve segments with small gaps between each other, due to noise in the original image. Thus, to improve the nerve tracing, the post-processing step performs morphological operations and traces missing connections. In addition, the algorithm computes all possible connection-paths between segments based on distance, angle, and intensity. The best connection-path is then chosen based on the Dijkstra algorithm.

From the automated nerve tracing, quantitative nerve parameters were extracted. For the current mosaic dataset, the algorithm provided the mosaic corneal nerve fiber length density (mCNFL), defined as the total length of all nerves in the mosaic divided by the mosaic area expressed in (mm/mm²), and the mosaic corneal nerve branch density (mCNBD) defined as the total number of branching points divided by the mosaic area expressed as the number of branching points per mm².

The inferocentral whorl region of the subbasal plexus normally contains the highest concentration of subbasal nerves, and this region has been analyzed separately in several studies. Here, subbasal nerve parameters were based on fasting whole blood samples acquired using venipuncture. L-dopa: Levodopa.

| Parameter | Description |
|-----------|-------------|
| Subject ID | Identification number assigned to each of the subjects in the study cohort (1 to 57) |
| Image name | File name assigned to each image in the wide-field mosaics dataset |
| Eye | Image and clinical data corresponding to right eye (RE) or left eye (LE) |
| Mosaic area | Area of the corneal subbasal nerve plexus represented in the mosaic image (mm²). In all cases, regions without image data (black or empty areas) were not included in the area calculation. |
| mCNFL | Mosaic corneal nerve fiber length density: the total length of all nerves in the mosaic divided by the mosaic area expressed in (mm/mm²) |
| mCNBD | Mosaic corneal nerve branch density: defined as total number of branching points divided by the mosaic area and expressed as the number of branching points per mm² (nr./ mm²) |
| wCNFL | Whorl corneal nerve fiber length density: defined as corneal subbasal nerve fiber length density in the whorl region (in mm/mm²), based on automated nerve tracing. wCNFL is provided for 800µm and 400µm diameter whorl regions in full and half-circle areas (see Fig. 5). Only values for eyes where the full circle contained image data are included. |
| wCNBD | Whorl corneal nerve branch density defined as total number of branching points in the whorl region divided by the mosaic area expressed as the number of branching points per mm². wCNBD is provided for the four different definitions of the whorl as for wCNFL. |
| mDCs | Density of mature dendritic cells in each mosaic, in cells/mm² of mosaic area. |
| imDCs | Density of immature dendritic cells in each mosaic, in cells/mm² of mosaic area. |
| GCs | Density of globular cells in each mosaic, in cells/mm² of mosaic area. |

Table 1. Study parameters related to the IVCM data obtained and provided in the mosaic dataset.

| Parameter | Description |
|-----------|-------------|
| Subject ID | Identification number of the subject in the cohort (57 subjects of which 2 were excluded). |
| Study Group | Controls, PD + RLS, or PD − RLS |
| Age | Subject age at time of study inclusion (years) |
| Sex | 1 = Male, 0 = Female |
| Smoking | Smoking status, 1 = yes, 0 = no |
| Coffee intake | Consumption of coffee (caps/day) |
| Intake of B12 supplements or multivitamins | 1 = yes, 0 = no |
| PD motor duration | Duration of motor symptoms (years) |
| RLS duration | Duration of restless legs syndrome (years) |
| L-dopa duration | Duration of treatment with L-dopa (years) |
| LEDD | L-dopa equivalent daily dose (mg) |
| Ongoing L-dopa therapy | 1 = yes, 0 = no |
| mH&Y (stage) | Modified Hoehn and Yahr scale for staging Parkinson’s symptoms and disability |
| IRLS | International RLS study group rating scale (IRLS): 0–40 |
| UENS | Utah Early Neuropathy Scale. Clinical rating scale for the assessment of peripheral neuropathy. |
| p-homocysteine | Concentration of homocysteine in plasma (µmol/L) |
| s-methylmalonic acid | Concentration of methylmalonic acid in serum (µmol/L) |
| p-pyridoxal-5’-phosphate | Concentration of pyridoxal-5’-phosphate in plasma (nmol/L) |
| s-ferritin | Concentration of ferritin in serum (µg/L) |

Table 2. List of clinical and demographic parameters linked to each study subject in the provided data set. Blood parameters were based on fasting whole blood samples acquired using venipuncture. L-dopa: Levodopa.
in the whorl region were analyzed by the automated tracing algorithm described above. Whorl corneal nerve fiber length (wCNFL) and whorl corneal nerve branch density (wCNBD) in the whorl region were automatically calculated from automated tracing with respect to four configurations; for nerves within a full circular region centered on the whorl center with either an 800 µm diameter or 400 µm diameter, and for the corresponding superior semi-circular regions (extending from 9 to 3 o’clock) only. Nerve analyses were performed across control, PD−RLS and PD+RLS groups, and again for controls vs. all PD participants.

Inflammatory cell analysis within the SBNP. Additionally, it is possible to analyze the mosaic dataset for the presence of inflammatory cells/dendritic cells (DCs), and with respect to the different DC subtypes whose morphologic features have been described in an earlier study. Here, two independent experienced observers performed morphological characterization and quantification of the inflammatory DCs present in the SBNP. The two observers were masked to the identity of each mosaic image. Three types of DCs were quantified: mature DCs, immature DCs and globular cells. The DC density values, expressed as cells per mm² of mosaic area for the various subtypes, were averaged across observers and across both eyes for all participants. This data is also provided along with the mosaic dataset.

Statistical analysis. Statistical analyses of presented data were performed using IBM SPSS statistics for Windows, version 25.0 (IBM Corp., Armonk, N.Y., USA). A two-tailed P value of < 0.05 was considered significant.

Data Records
Data for the wide field mosaic images of the corneal subbasal plexus that were acquired for PD patients and control participants are provided. The Excel file contains the numeric data and the corresponding mosaic image numbers, and is therefore the ‘key’ to the mosaic image dataset. IVCM mosaic images represent the largest mosaic per eye and are provided in TIFF format, labeled with the subject ID number (01 to 57 – two participants were excluded hence non-consecutive numbering) and the eye (RE for right eye and LE for left eye). Table 1 details the parameters associated with the SBNP mosaic dataset. In addition, we provide in the same file the clinical parameters linked to each study subject (Table 2). Finally, we provide folders for each eye (in ZIP format) containing the raw, non-stitched IVCM images used to create each corresponding mosaic image.
Technical Validation

The average (mean ± standard deviation) percentage of SNP-classified images from a given eye was 59.2 ± 15.8%. The overall runtime of the mosaic image generation process is dominated by the image registration step, which exhibits a quadratic runtime behavior with respect to the SBNP-filtered dataset size when registering all possible image pairs. The following overall runtimes are therefore not normally distributed and are given as median (interquartile range). The overall runtime measured in the study process pipeline (i.e. not applying the runtime optimizations), was 88.6 (45.8, 166.1) minutes per eye (Fig. 1a). After employing the runtime optimizations, particularly including scaling down the images prior to phase correlation, the runtime of the entire process decreased to 3.0 (1.6, 5.7) minutes per eye. The resulting mosaic image quality was comparable with both approaches, as examined by visual comparison. Figure 1 shows a scatter plot of the runtime for mosaic generation in relation to the size of respective mosaic images in the study cohort, and to the number of individual raw IVCM images used to generate each corresponding mosaic. Runtimes are based on a Windows PC system (Core2 Duo, E8400, 2 × 3 GHz, 6GB RAM).

The average (mean ± standard deviation) mosaic size per eye was 7.69 ± 3.53 mm² across a total of 106 mosaics, for the original process used for study evaluation. This corresponds to a mean enhancement factor of 48 across all 106 mosaics, meaning an equivalent mean tiled area of 48 individual IVCM image frames. Figure 1b shows the distribution of the number of mosaics with corresponding enhancement factor in the present dataset.
The data presented here represents the mosaic with the largest size for each eye, differing slightly from prior analyses where in some cases average values from several mosaics per eye were used \(^9\). It is interesting to note that using the runtime-optimized algorithms, the average size of the largest mosaic image for a given eye decreased to 7.15 ± 3.30 mm\(^2\), with either no area reduction or an area reduction of less than 5% of the original mosaic image area in 69% of the mosaics. It is worth noting that – for both the optimized and the non-optimized process alike – the original images that could not be integrated into the single largest mosaic image per eye are still assembled into separate, smaller mosaic images. Figure 2(a–c) shows representative SBNP mosaics from the control, PD + RLS and PD − RLS groups.

Inflammatory cell type

|                        | mDCs  | imDCs | GCs  |
|------------------------|-------|-------|------|
| Mean difference        | 9.3   | −4.9  | −0.8 |
| SD                     | 12.7  | 30.0  | 2.6  |
| Lower 95% LOA          | −15.6 | −63.8 | −5.9 |
| Upper 95% LOA          | 34.3  | 54.0  | 4.3  |
| Pearson's r            | 0.68  | 0.74  | 0.98 |

Table 3. Overview of inter-observer differences in dendritic cell quantification from mosaic images. Values represent the mean difference between the two observers, standard deviation of difference and lower and upper bounds of the 95% limits of agreement (LOA) for dendritic cell density in cells/mm\(^2\) of mosaic area, for each given cell type. Identification and quantification of inflammatory cells was based on three cell types: mDCs: Mature dendritic cells, imDCs: immature dendritic cells, and GCs: globular cells. The correlation coefficient between observers (Pearson's r) is shown for each cell type.
indicated whorl regions. We provide the nerve parameter data for these analyses as part of the current dataset. Example comparisons of mCNFL and wCNFL across the various groups are given in Fig. 4(a,b) and Fig. 5(a–d).

The validity of the manual inflammatory cell quantification in mosaics by the two observers was determined by the Bland–Altman analysis method of inter-observer agreement53. The mean, standard deviation (SD) and the 95% limits of agreement (LOA) between observers for the difference in cell density for each cell type across all mosaics is presented in Table 3, along with the correlation between observers measured by Pearson’s r. As an example of the inflammatory cell data, the density of mature and immature dendritic cells (mDCs, imDCs, respectively), and globular cells (GCs) are plotted across the three subject groups (Fig. 6a–c).

Code availability
Computational codes used to, firstly, perform the depth-corrected mosaics synthesis used in the study and, secondly, for automated nerve tracing were developed by the academic institutions of Karlsruhe Institute of Technology and University of Padua, respectively, and are exclusively intended for scientific research use30,31. The developers of the respective algorithms are willing to apply the code to user-supplied raw IVCM data in the form of academic collaborations. Interested parties are requested to contact the respective researchers for mosaic creation (Allgeier) and automated nerve analyses (Scarpa).

References

1. Feigin, V. L. et al. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. Neurology 16, 877–897 (2017).
2. Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30, 1591–1601 (2015).
3. Toth, C. et al. Levodopa, methylnalonic acid, and neuropathy in idiopathic Parkinson disease. Annals of neurology 68, 28–36 (2010).
4. Doppler, K. et al. Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology. Acta neuropathologica 128, 99–109 (2014).
5. Gómez-Esteban, J. C. et al. Restless legs syndrome in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 22, 1912–1916 (2007).
6. Möller, J. C., Unger, M., Stiasny-Kolster, K. & Oertel, W. H. Restless Legs Syndrome (RLS) and Parkinson’s disease (PD)-related disorders or different entities? Journal of the neurological sciences 289, 135–137 (2010).
7. Angelini, M., Negrotti, A., Marchesi, E., Bonavina, G. & Calzetti, S. A study of the prevalence of restless legs syndrome in previously untreated Parkinson’s disease patients: absence of co-morbid association. Journal of the neurological sciences 310, 286–288 (2011).
8. Rijksman, R. M., Schoolderman, L. F., Rundervoort, R. S. & Louter, M. Restless legs syndrome in Parkinson’s disease. Parkinsonism & related disorders 20(Suppl 1), S5–9 (2014).
9. Malik, R. A. et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia 46, 683–688 (2003).
10. Messmer, E. M., Schmid-Tannwald, C., Zapp, D. & Kampik, A. In vivo confocal microscopy of corneal small fiber damage in diabetes mellitus. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 248, 1307–1312 (2010).
11. Perkins, B. A. et al. Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia 61, 1856–1861 (2018).
12. Jiang, M. S., Yuan, Y., Gu, Z. X. & Zhuang, S. L. Corneal confocal microscopy for assessment of diabetic peripheral neuropathy: a meta-analysis. The British journal of ophthalmology 100, 9–14 (2016).
13. Tavakoli, M. et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes care 33, 1792–1797 (2010).
14. Petropoulos, I. N. et al. Corneal nerve loss detected with corneal confocal microscopy is symmetrical and related to the severity of diabetic polyneuropathy. Diabetes Care 36, 3646–3651 (2013).
15. Petropoulos, I. N. et al. Rapid automated diagnosis of diabetic peripheral neuropathy with in vivo corneal confocal microscopy. Investigative ophthalmology & visual science 55, 2071–2078 (2014).
16. Lagali, N. S. et al. Reduced Corneal Nerve Fiber Density in Type 2 Diabetes by Wide-Area Mosaic Analysis. Invest Ophthalmol Vis Sci 58, 6318–6327 (2017).
17. Ferdoussi, M. et al. Diabetic Neuropathy Is Characterized by Progressive Corneal Nerve Fiber Loss in the Central and Inferior Whorl Regions. Investigative ophthalmology & visual science 61, 48 (2020).
18. Muller, L. J., Pels, L. & Vrensen, G. F. Ultrastructural organization of human corneal nerves. Investigative ophthalmology & visual science 37, 476–488 (1996).
19. Oliveira-Soto, L. & Efron, N. Morphology of corneal nerves using confocal microscopy. Cornea 20, 374–384 (2001).
20. Muller, L. J., Marfurt, C. F., Kruse, F. & Tervo, T. M. Corneal nerves: structure, contents and function. Exp. Eye Res. 76, 521–542 (2003).
21. Eghrari, A. O., Riazuddin, S. A. & Gottsch, J. D. Overview of the Cornea: Structure, Function, and Development. Progress in molecular biology and translational science 134, 7–23 (2015).
22. Oliveira-Soto, L. & Efron, N. Morphology of corneal nerves in soft contact lens wear. A comparative study using confocal microscopy. Ophthalmic & physiological optics: the journal of the British College of Ophthalmic Opticians (Optometrists) 23, 163–174 (2003).
23. Jabert, J., Stapleton, F., Papas, E., Sweeney, D. F. & Coroneo, M. In vivo confocal microscopy of the human cornea. The British journal of ophthalmology 87, 225–236 (2003).
24. Stachs, O., Guthoff, R. F. & Aumann, S. In Vivo Confocal Scanning Laser Microscopy in High Resolution Imaging in Microscopy and Ophthalmology: New Frontiers in Biomedical Optics (ed. Bille, J. F.) 263–284 (Springer International Publishing, Cham, 2019).
25. Tavakoli, M., Petropoulos, I. N. & Malik, R. A. Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot. Journal of diabetes science and technology 7, 1179–1189 (2013).
26. Lagali, N. et al. Focused Tortuosity Definitions Based on Expert Clinical Assessment of Corneal Subbasal Nerves. Investigative ophthalmology & visual science 56, 5102–5109 (2015).
27. Kass-Iliyva, L. et al. Small fiber neuropathy in Parkinson's disease: A clinical, pathological and corneal confocal microscopy study. Parkinsonism & related disorders 21, 1454–1460 (2015).
28. Podgorny, P. J., Suchowersky, O., Romanchuk, K. G. & Feasby, T. E. Evidence for small nerve fiber neuropathy in early Parkinson's disease. Parkinsonism & related disorders 28, 94–99 (2016).
29. Misra, L. S., Kersten, H. M., Roxburgh, R. H., Danesh-Meyer, H. V. & McGhee, C. N. Corneal nerve microstructure in Parkinson's disease. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia 39, 53–58 (2017).
30. Andréasson, M. et al. Parkinson's disease with restless legs syndrome—an in vivo corneal confocal microscopy study. NPJ Parkinsons Dis 7, 4 (2021).
31. Lagali, N. S. et al. Wide-field corneal subbasal nerve plexus mosaics in age-controlled healthy and type 2 diabetes populations. Sci Data 5, 180075 (2018).
32. Whinton, P. S. Inflammation as a causative factor in the aetiology of Parkinson's disease. British journal of pharmacology 150, 963–976 (2007).
33. Tansey, M. G. & Goldberg, M. S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neuropathology of disease 37, 510–518 (2010).
34. De Lella Excurra, A. L., Chertoff, M., Ferrari, C., Griciarena, M. & Pittosi, F. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiology of disease 37, 630–640 (2010).
35. Lagali, N. S. et al. Dendritic cell maturation in the corneal epithelium with onset of type 2 diabetes is associated with tumor necrosis factor receptor superfamily member 9. Sci Rep 8, 14248 (2018).
36. Allen, R. P. et al. Restless legs syndrome/Willis–Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria–history, rationale, description, and significance. Sleep Med 15, 860–873 (2014).
37. Goetz, C. G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19, 1020–1028 (2004).
38. Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427–442 (1967).
39. Singleton, J. R. et al. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Sys 13, 218–227 (2008).
40. Walters, A. S. et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4, 121–132 (2003).
41. De Cock, V. C. et al. Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society 27, 743–749 (2012).
42. Michaud, M., Lavigne, G., Desautels, A., Potier, G. & Montplasir, J. Effects of immobility on sensory and motor symptoms of restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society 17, 112–115 (2002).
43. Bartschat, A. et al. Fuzzy tissue detection for real-time focal control in corneal confocal microscopy. at - Automatisierungs technik 67, 879–888 (2019).
44. Forooz, H., Zerubia, J. B. & Berthod, M. Extension of phase correlation to subpixel registration. IEEE transactions on image processing: a publication of the IEEE Signal Processing Society 11, 188–200 (2002).
45. Allgeier, S. et al. Elastische Registrierung von in-vivo-CLSM-Aufnahmen der Kornea. in Bildverarbeitung für die Medizin 2011: Algorithmen - Systeme - Anwendungen Proceedings des Workshops vom 20-22 März 2011 in Lübeck (eds. Handels, H., Ehrhardt, J., Deserno, T. M., Meinzer, H.-P. & Tolxdorff, T.) 149–153 (Springer Berlin Heidelberg, Berlin, Heidelberg, 2011).
46. Guimaraes, P., Wigdahl, J. & Ruggeri, A. A Fast and Efficient Technique for the Automatic Tracing of Corneal Nerves in Confocal Imaging. Transl Vis Sci Technol 5, 7 (2016).
47. Scarpa, F., Grisan, E. & Ruggeri, A. Automatic recognition of corneal nerve structures in images from confocal microscopy. Investigative ophthalmology & visual science 49, 4801–4807 (2008).
48. Dijkstra, E. W. A note on two problems in connexion with graphs. Numerische Mathematik 1, 269–271 (1959).
49. Patel, D. V. & McGhee, C. N. Mapping of the normal human corneal sub-Basal nerve plexus by in vivo laser scanning confocal microscopy. Invest. Ophthalmol. Vis. Sci. 46, 4485–4488 (2005).
50. Utsunomiya, T. et al. Imaging of the Corneal Subbasal Whorl-like Nerve Plexus: More Accurate Depiction of the Extent of Corneal Nerve Damage in Patients With Diabetes. Invest. Ophthalmol. Vis. Sci. 56, 5417–5423 (2015).
51. Pritchard, N. et al. Utility of Assessing Nerve Morphology in Central Cornea Versus Whorl Area for Diagnosing Diabetic Peripheral Neuropathy. Cornea 34, 756–761 (2015).
52. Bland, J. M. & Altman, D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (London, England) 1, 307–310 (1986).

Acknowledgements

Authors wish to acknowledge the kind assistance and support of the outpatient clinic at Center for Neurology and Karolinska University Hospital, Stockholm where study participants were recruited to the original study that was approved by the regional ethical board of Stockholm, Sweden (ref. nr 2018/264-31/2 (2019-03158). The study was funded by Hofgren's fond, NEURO Sweden. Parts of this work were funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; project nr. 273371152).
Author contributions
R.A.B. designed and conducted evaluations of the subbasal nerve plexus related parameters, analyzed data for validation purposes, and wrote the manuscript. N.L. designed and conceived the original IVCM study, performed IVCM examinations, analyzed data for validation purposes, interpreted data, and contributed to writing the manuscript. S.A., B.K., A.B. and R.M. conceived, developed, tested and optimized mosaic image generation algorithms, provided the mosaics, and contributed to writing the manuscript. F.S. and A.C. developed and customized the algorithm for the automated nerve fiber tracing, performed automated nerve parameter analysis and data extraction from whole and partial mosaics, and contributed to writing the manuscript. M.B. analyzed mosaics and manually quantified inflammatory cells. M.A. conceived and designed the original clinical study, designed and conducted the Parkinson's disease-specific neurological examinations, and obtained all clinical parameter data. P.S. conceived and designed the original clinical study, and designed, evaluated, and interpreted the Parkinson's disease specific neurological examinations. T.P.U. contributed to study coordination, implementation and drafting the manuscript. All authors critically reviewed and revised the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to R.A.B. or N.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0/ applies to the metadata files associated with this article.

© The Author(s) 2021